Azoospermia after testosterone gel treatment

Abstract

A case report presented azoospermia in 30 y.o. man after 4 months of 50 mg daily dose testosterone gel treatment. The absence of sperm in ejaculate urged interruption of couple infertility treatment by means of IVF, oocytes cryopreservation was performed. Initiation of testosterone replacement monotherapy should be avoided in men wishing to preserve fertility.

Keywords

testosterone replacement therapy / infertility / azoospermia

References

[1] 1.Dohle GR, Arver S, Bettocchi C, et al. EAU guidelines on male hypogonadism. 2017. http://uroweb.org/guideline/male-hypogonadism

[2] 2.Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15. doi: 10.3109/13685538.2015.1004049.

[3] 3.Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34(4):828-837. doi: 10.2337/dc10–1233.

[4] 4.Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199(8):548-551. doi: 10.5694/mja13.10111.

[5] 5.Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809-825. doi: 10.1016/j.eururo.2011.06.037.

[6] 6.Корнеев И.А., Глазнева С.Ю. Возрастной дефицит андрогенов и расстройства мочеиспускания // Нефрология. – 2008. – Т. 4. – № 12. – С. 72–76. [Korneyev IA, Glazneva SYu. Late-onset hypogonadism and lower urinary tract symptoms. Nephrology. 2008;4(12):72-76. (In Russ.)]

[7] 7.Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168(3):445-455. doi: 10.1530/eje-12-0890.

[8] 8.Roth MY, Shih G, Ilani N, et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception. 2014;90(4):407-412. doi: 10.1016/j.contraception.2014.05.013.

[9] 9.Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336(8721):955-9. doi: 10.1016/0140-6736(90)92416-f.

[10] 10.Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009;94(6):1910-1915. doi: 10.1210/jc.2008-1846.

[11] 11.Lipshultz LI, Ramasamy R, Armstrong JM. Preserving fertility in the hypogonadal patient: an update. Asian J Androl. 2015;17(2):197-200. doi: 10.4103/1008-682x.142772.

[12] 12.Мсхалая Г.Ж., Тишова Ю.А., Калинченко С.Ю. Влияние терапии гипогонадизма препаратом Андрогель на показатели сперматогенеза // Эффективная фармакотерапия. Эндокринология. – 2013. – Т. 1. – № 9. – С. 40–44. [Mskhalaya GZ, Tishova YA, Kalinchenko SY. The effect of treatment of hypogonadism drug Androgel on indicators of spermatogenesis. Effective pharmacotherapy. Endocrinology. 2013;1(9):40-44. (In Russ.)]

[13] 13.Mskhalaya G, Tishova Y, Kalinchenko S. Influence of testosterone gel treatment on spermatogenesis in men with hypogonadism. Gynecol Endocrinol. 2014;30(Suppl.1):22-24. 10.3109/09513590.2014.945777.

RIGHTS & PERMISSIONS

Korneyev I.A., Zasseev R.D.